Search research articles
Contact Us
Filters
Showing results (161-170 of 185) with videos related to
Page
of 19
Sort By:
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
May 30, 2015
[Neoadjuvant chemotherapy in muscular invasive bladder cancer: Complications and consequences with cystectomy]
S Benadiba, H Gauthier, G Ploussard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 26, 2003
Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients
J P Droz, X Muracciole, N Mottet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 25, 2015
First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†
A Ravaud, S Oudard, M De Fromont, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 26, 2011
Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial
A Fléchon, D Pouessel, C Ferlay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 16, 2002
Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients
L Zelek, P Cottu, M Tubiana-Hulin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 14, 2007
Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP)
S Culine, P Kerbrat, A Kramar, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
July 13, 2018
[Impact of neoadjuvant chemotherapy on the peri-operative morbidity of radical cystectomy for muscle invasive bladder cancer]
C Michel, D Vordos, C Dumont, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 14, 2004
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer
P Fumoleau, R Largillier, C Clippe, et al.
British Journal of Cancer
|
August 20, 2009
Increased expression of class III beta-tubulin in castration-resistant human prostate cancer
S Terry, G Ploussard, Y Allory, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
February 16, 2022
Perioperative results of radical cystectomy after neoadjuvant chemotherapy according to the implementation of ERAS pathway
T-R Dobé, Y Belhadj, C Michel, et al.
Page
of 19
Search research articles
Search
Showing results (161-170 of 185) with videos related to
Sort By:
Page
of 19
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
May 30, 2015
[Neoadjuvant chemotherapy in muscular invasive bladder cancer: Complications and consequences with cystectomy]
S Benadiba, H Gauthier, G Ploussard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 26, 2003
Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients
J P Droz, X Muracciole, N Mottet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 25, 2015
First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†
A Ravaud, S Oudard, M De Fromont, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 26, 2011
Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial
A Fléchon, D Pouessel, C Ferlay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 16, 2002
Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients
L Zelek, P Cottu, M Tubiana-Hulin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 14, 2007
Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP)
S Culine, P Kerbrat, A Kramar, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
July 13, 2018
[Impact of neoadjuvant chemotherapy on the peri-operative morbidity of radical cystectomy for muscle invasive bladder cancer]
C Michel, D Vordos, C Dumont, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 14, 2004
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer
P Fumoleau, R Largillier, C Clippe, et al.
British Journal of Cancer
|
August 20, 2009
Increased expression of class III beta-tubulin in castration-resistant human prostate cancer
S Terry, G Ploussard, Y Allory, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
February 16, 2022
Perioperative results of radical cystectomy after neoadjuvant chemotherapy according to the implementation of ERAS pathway
T-R Dobé, Y Belhadj, C Michel, et al.
Page
of 19